Placebo + ABBV-8E12
Phase 2Terminated 0 views this week 0 watching💤 Quiet
Interest: 27/100
27
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Progressive Supranuclear Palsy
Conditions
Progressive Supranuclear Palsy
Trial Timeline
Dec 12, 2016 → Nov 20, 2019
NCT ID
NCT02985879About Placebo + ABBV-8E12
Placebo + ABBV-8E12 is a phase 2 stage product being developed by AbbVie for Progressive Supranuclear Palsy. The current trial status is terminated. This product is registered under clinical trial identifier NCT02985879. Target conditions include Progressive Supranuclear Palsy.
What happened to similar drugs?
2 of 20 similar drugs in Progressive Supranuclear Palsy were approved
Approved (2) Terminated (4) Active (14)
Hype Score Breakdown
Clinical
12
Activity
0
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02985879 | Phase 2 | Terminated |
Competing Products
20 competing products in Progressive Supranuclear Palsy